Sign in Subscribe

article

A collection of 636 issues

Childhood Cancer Survivors Underutilize Colorectal Cancer Screening

Skip to content The CRC Digest ▪ SCREENING Childhood Cancer Survivors Underutilize Colorectal Cancer Screening A French national study found that childhood cancer survivors participated in fecal immunochemical testing at rates of 20.0% to 23.2% across three screening periods—significantly lower than the general population—despite their elevated CRC

KRAS G12D Inhibitor Reshapes Immune Landscape, Enhances NK Cell Therapy

Skip to content The CRC Digest ◇ RESEARCH KRAS G12D Inhibitor Reshapes Immune Landscape, Enhances NK Cell Therapy Preclinical research shows that KRAS G12D inhibition with MRTX1133 remodels the tumor immune environment by reducing immunosuppressive cells and facilitating infiltration of natural killer and CD8+ T cells, reversing systemic immunosuppression and restoring

Dual Immune Checkpoint Blockade Shows Early Survival Benefit in MSI-H Metastatic CRC

Skip to content The CRC Digest ◆ TRIAL DATA Dual Immune Checkpoint Blockade Shows Early Survival Benefit in MSI-H Metastatic CRC Research comparing dual CTLA-4/PD-1 blockade versus anti–PD-1 alone in MSI-H (microsatellite instability-high) metastatic colorectal cancer. (Clinical Colorectal Cancer) This content is informational only and does not constitute medical

ESMO Updates Guidelines for Metastatic Colorectal Cancer

Skip to content The CRC Digest ● REGULATORY ESMO Updates Guidelines for Metastatic Colorectal Cancer New ESMO Clinical Practice Guidelines establish structured treatment algorithms driven by MMR/MSI status, ECOG performance, tumor location, and extended molecular profiling including RAS, BRAF, HER2, and KRAS G12C. Key updates include first-line FOLFOX-encorafenib-cetuximab for BRAF

Trimodal prehabilitation studied for anxiety and quality of life in CRC surgery

Skip to content The CRC Digest Trimodal prehabilitation studied for anxiety and quality of life in CRC surgery An interim analysis of 45 patients (20 in prehabilitation, 25 in standard care) in a randomized trial evaluated whether a program combining exercise, nutrition, and psychological counseling could affect perioperative anxiety and

Inflammatory markers linked to fatigue up to 3 years after CRC surgery

Skip to content The CRC Digest Inflammatory markers linked to fatigue up to 3 years after CRC surgery A multicenter study tracked 16 inflammatory biomarkers and fatigue in CRC patients from surgery through 36 months, finding longitudinal associations that may help identify patients at risk for persistent fatigue. (Cancer Medicine)

Endocrine side effects vary by immunotherapy regimen in CRC

Skip to content The CRC Digest Endocrine side effects vary by immunotherapy regimen in CRC A network meta-analysis of six randomized trials found that pembrolizumab and ICI plus tyrosine kinase inhibitor combinations significantly increased hypothyroidism risk, while hyperthyroidism was higher with ICI-TKI and ICI-chemotherapy-antiangiogenic regimens. (Frontiers in Immunology) This content

Colon capsule endoscopy system evaluated in multicenter study as noninvasive screening alternative

Skip to content The CRC Digest ▪ SCREENING Colon capsule endoscopy system evaluated in multicenter study as noninvasive screening alternative A prospective multicenter study at three hospitals in China assessed the CC100 colon capsule endoscopy system's diagnostic accuracy and complete visualization rates, offering a minimally invasive alternative to conventional

Colonoscopy linked to lower CRC risk in adults aged 75–85 in Korean nationwide study

Skip to content The CRC Digest ▪ SCREENING Colonoscopy linked to lower CRC risk in adults aged 75–85 in Korean nationwide study In a study of adults aged 75 to 85, two matched cohorts of 19,005 individuals each were compared: colonoscopy was associated with a reduced incidence of colorectal

Blood-based cfDNA test trial aims to reduce CRC screening disparities

Skip to content The CRC Digest ▪ SCREENING Blood-based cfDNA test trial aims to reduce CRC screening disparities A randomized trial is underway to test whether offering an FDA-approved cell-free tumor DNA blood test as an expanded screening option improves participation rates, especially among lower-income and racial/ethnic minoritized groups who